Research Article

Genotype-phenotype correlation in neurofibromatosis type-1: NF1 whole gene deletions lead to high tumor-burden and increased tumor-growth

Lennart Well1*, Kimberly Döbel1, Lan Kluwe1,2,3, Peter Bannas1, Said Farschtschi2, Gerhard Adam1, Victor-Felix Mautner2, Johannes Salamon1

1 Department of Diagnostic and Interventional Radiology and Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 2 Department of Neurology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 3 Department of Maxillofacial Surgery, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

* l.well@uke.de

Abstract

Neurofibromatosis type-1 (NF1) patients suffer from cutaneous and subcutaneous neurofibromas (CNF) and large plexiform neurofibromas (PNF). Whole gene deletions of the NF1 gene can cause a more severe phenotype compared to smaller intragenic changes. Two distinct groups of NF1 whole gene deletions are type-1 deletions and atypical deletions. Our aim was to assess volumes and averaged annual growth-rates of CNF and PNF in patients with NF1 whole gene deletions and to compare these with NF1 patients without large deletions of the NF1 gene.

We retrospectively evaluated 140 whole-body MR examinations of 38 patients with NF1 whole gene deletions (type-1 group: n = 27/atypical group n = 11) and an age- and sex matched collective of 38 NF1-patients. Age-dependent subgroups were created (0–18 vs >18 years). Sixty-four patients received follow-up MRI examinations (NF1 whole gene deletion n = 32/control group n = 32). Whole-body tumor-volumes were semi-automatically assessed (MedX, V3.42). Tumor volumes and averaged annual growth-rates were compared.

Median tumor-burden was significantly higher in the type-1 group (418ml; IQR 77 – 950ml, p = 0.012) but not in the atypical group (356ml;IQR 140–1190ml, p = 0.099) when compared to the controls (49ml; IQR 11–691ml). Averaged annual growth rates were significantly higher in both the type-1 group (14%/year; IQR 45–36%/year, p = 0.004) and atypical group (11%/year; IQR 5–23%/year, p = 0.014) compared to the controls (4%/year; IQR1–8%/year). Averaged annual growth rates were significantly higher in pediatric patients with type-1 deletions (21%/year) compared with adult patients (8%/year, p = 0.014) and also compared with pediatric patients without large deletions of the NF1 gene (3.3%/year, p = 0.0015).

NF1 whole gene deletions cause a more severe phenotype of NF1 with higher tumor burden and higher growth-rates compared to NF1 patients without large deletions of the NF1 gene.
gene. In particular, pediatric patients with type-1 deletions display a pronounced tumor growth.

Author summary

Neurofibromatosis type-1 (NF1) is an autosomal dominantly inherited tumor predisposition syndrome and is caused by a variety of mutations of the NF1 gene. Large deletions encompassing the entire NF1 gene are known to be associated with a more severe clinical phenotype. A hallmark feature of NF1 is the development of different benign tumors: cutaneous or subcutaneous neurofibromas (CNF) and the potentially large plexiform neurofibromas (PNF). Importantly, PNF can undergo transformation into malignant peripheral nerve sheath tumors, which contribute to the increased mortality of NF1 patients. Identified risk factors for malignant transformation are NF1 whole gene deletions, large whole-body tumor burden and a high number of subcutaneous neurofibromas. We performed semi-automated volumetry of these tumors to determine volumes and growth rates of CNF and PNF in patients with whole gene deletions and a control group of NF1 patients without large deletions of the NF1 gene. Our results indicate that NF1 whole gene deletions lead to higher tumor burden and higher growth rates. In particular, pediatric NF1 patients with a specific type of whole gene deletion (type-1 deletion) exhibit rapid growth of PNF. We therefore suggest that these patients should be monitored in close intervals to evaluate tumor growth and risk of malignant transformation.

Introduction

Neurofibromatosis type-1 (NF1) is an autosomal dominantly inherited tumor predisposition syndrome with an incidence of 1 in 3000 [1, 2]. NF1 is caused by heterozygous inactivation of the NF1 tumor suppressor gene on 17q11.2 [3]. A variety of mutations of the NF1 gene can lead to a manifestation of the disease [4]. Large deletions encompassing the entire NF1 gene and its flanking regions (NF1 whole gene deletions) have been identified in 5–11% of patients [5–8].

The most frequent NF1 whole gene deletions are the so called type-1 deletions accounting for 70–80% of large NF1 deletions [9, 10]. Type-1 deletions have a size of 1.4Mb and include 14 protein-coding genes as well as four microRNA genes [9–11]. These deletions usually occur as germline mutations, which are present in all cells of affected patients [12, 13]. Less frequently identified are so-called atypical deletions, distinguishable by size, breakpoint location, number of affected genes and frequency of mosaicism [4].

NF1 whole gene deletions of the NF1 gene are associated with a more severe clinical phenotype of NF1, including dysmorphic facial features, intellectual disability, congenital cardiac anomalies and increased numbers of cutaneous and subcutaneous neurofibromas (CNF) and plexiform neurofibromas (PNF) [14–17].

The development of CNF and PNF is a hallmark feature of NF1 [18]. PNF can grow to a large size and can cause clinical complications such as skeletal deformation, compression of organs and vessels or neurological impairment [19]. Furthermore, PNF can undergo transformation into malignant peripheral nerve sheath tumors (MPNST) in 8–13% of NF1 patients. NF1 whole gene deletions have been identified as a risk factor for development of MPNST [20, 21]. Other risk factors for growth of NF1-associated tumors are young age, large whole-body...
tumor burden, female sex and a high number of subcutaneous neurofibromas [22–24]. To quantify growth of tumors and to assess the potential risk of malignant transformation of PNF to MPNST, NF1 patients repeatedly undergo whole-body MRI examinations [25, 26]. Semi-automated volumetry has been demonstrated to be a reliable tool for quantification of volume and growth of internal tumors [27–30]. However, quantification of CNF by semi-automated volumetry has not been reported as of yet.

Previous studies have shown that NF1 whole gene deletions can be associated with a higher tumor burden in affected patients compared with patients without large deletions [28]. However, growth rates of tumors in these patients have not been determined.

Therefore, we aimed to assess volumes and averaged annual growth rates of CNF and PNF in NF1 patients with NF1 whole gene deletions, and to compare these with NF1 patients without large deletions of the NF1 gene.

Material and methods

Ethics statement

This retrospective, Health Insurance Portability and Accountability Act (HIPAA)-compliant study has been approved by the ethical-review board of the Ärztekammer Hamburg (no. PV7214) and complied with the local data protection guidelines as well as the Declaration of Helsinki and its later amendments. Written informed consent was obtained from all participants or their legal representatives.

Study population

In this study, 38 patients with NF1 whole gene deletions (mean age 25.8 years; range 4–58 years; 20 females) were included. This group consisted of 27 patients with type-1 deletions (type-1 group; n = 27; mean age 24.6; range 4–53 years; 13 females) and 11 patients with atypical deletions (atypical group; n = 11; mean age 28.7; range 4–58 years; 6 females). These patients (type-1 and atypical) were compared to an age- and sex-matched group of 38 patients without large deletions of the NF1 gene (control group) (mean age 25.2; range 4–53 years; 20 females). Several patients of this study population (15/76 patients) have been investigated in a previous study (type-1 group: 7/27; atypical group 2/11 patients; control group: 6/38 patients) [28].

Inclusion criteria for this study for both, study group and control group, were fulfillment of the National Institutes of Health (NIH) diagnostic criteria for NF-1 [31], genetic analysis of the NF1 gene and availability of at least one whole-body MRI examination for volumetry. Exclusion criteria were the inability to undergo MRI examinations or lack of genetic analysis. Additionally, patients with suspected or confirmed mosaic deletions were excluded from this study to prevent a potential bias as genetic mosaicism can induce mild phenotypes. The NF1 gene mutations for each patient are provided in supporting information S1 and S2 Tables.

All patients were screened for whole gene deletions using multiple intragenic microsatellite markers or directly with a multiple-ligation-dependent primer amplification assay [7, 32]. Patients without whole gene deletions were further screened for intragenic minor NF1 mutations by direct Sanger sequencing (Supporting information S1 and S2 Tables) [33]. All patients included received clinical care and genetic counseling at our outpatient clinic.

For subgroup analysis, patients were further divided by age at the timepoint of the first MRI examination into children/adolescents ≤18 years of age (type-1 group: n = 8; mean age 11.0 years, range 4–18 years / atypical group: n = 3; mean age 9.3 years; range 4–15 years / control group: n = 12; mean age 11.1 years; range 3–18 years) and adults > 18 years of age (type-1
group: n = 19; mean age 30.3 years; range 19–53 years / atypical group: n = 8; mean age 36 years; range 21–58 years / control group: n = 26; mean age 31.7 years; range 19–56 years)[29].

MRI examinations and volumetry
A total of 140 MRI examinations of all included patients were performed as part of the standard clinical care between September 2003 and March 2019 at 1.5 T or 3 T (Siemens Avanto or Skyra, Siemens Healthineers, Erlangen, Germany). MRI-sequences were T1w TSE coronal (1.5 T:TR 572 ms; TE 9 ms; FA 90˚; in plane resolution 0.88 x 0.88; slice thickness 6 mm / 3 T: TR 731 ms; TE 11 ms; FA 160˚; in plane resolution 0.98 mm x 0.89 mm; slice thickness 7 mm), T2w TIRM coronal (1.5 T: TR 3110 ms; TE 101 ms; FA 150˚; in plane resolution 0.94 mm x 2.1 mm; slice thickness 7 mm / 3 T: TR 4000 ms; TE 45 ms; FA 130˚; in plane resolution 1.29 mm x 1.03 mm; slice thickness 7 mm), T2w HASTE TIRM axial (1.5 T: TR 4910 ms; TE 104 ms; FA 150˚; in plane resolution 0.96 mm x 1.9 mm; slice thickness: 8 mm / 3 T: TR 1200 ms; TE 85 ms, FA 148˚; in plane resolution 1.17 mm x 1.17 mm; slice thickness 8 mm) and T2w TSE sagittal (1.5 T: TR 4180 ms; TE 102 ms; FA 170˚; in plane resolution 0.63 mm x 1.25 mm; slice thickness 3.5 mm / 3 T: TR 4600 ms; TE 96 ms; FA 160˚; in plane resolution 0.68 mm x 0.63 mm; slice thickness 3 mm) sequences. No contrast enhanced sequences were performed.

32/38 patients (84.2%) of the study group (type-1 group: n = 22/27; atypical group: n = 10/11) and 32/38 patients (84.2%) of the control group received follow-up MRI examinations with a mean time interval between examinations of 6.3 years in the study group (range 2.0–12.7 years) and 5.5 years in the control group (range 2.0–9.8 years). 12 patients received only one MRI examination (type-1 group: 5/27; atypical group: 1/11; control group: 6/32).

Image analysis and volumetry
All MRI examinations were evaluated regarding the presence of CNF or PNF including rare discrete internal tumors (smaller singular nodular lesions)[22]. PNF and discrete internal tumors represent the patient’s internal tumor load[22].

CNF were identified as singular circular-shaped and homogenous hyperintense lesions on T2-weighted images with random cutaneous or subcutaneous distribution [34, 35] (Fig 1A–1C). It was not possible to satisfactorily distinguish cutaneous neurofibromas from subcutaneous ones, therefore the two entities were measured as one group. PNF were identified by their characteristic appearance as polylobulated, hyperintense masses on T2-weighted images spreading along peripheral nerves [29, 34] (Fig 1D and 1E).

Volumetry of tumors was performed using MedX software (V3.42) on fat-saturated T2-weighted images (Fig 1). MedX utilizes a heuristic-based semi-automated method for segmentation and measurement [27]. Previous studies have restricted volumetry of tumors to tumor sizes of $\geq$ 3 cm [29]. To evaluate if volumetry of smaller tumors is feasible and reproducible with MedX, a set of gelatin phantoms was built: Disposable syringes were filled with dissolved gelatin (Rainin Pipet-Lite XLS) (volumes: 0.1ml, 0.2ml, 0.3ml, 0.4ml, 0.5ml, 1.0ml, 2ml) and stored at 4˚C overnight. The syringes were then cut open and the hardened gelatin was extracted (Supporting information S1 Fig). MRI scans of these phantoms were performed, using the coronal T2-weighted TIRM sequence described above (Supporting information S3 Table). Volumes were then measured for three times by one reader as described below (Supporting information S3 Table). The measured volumes did not significantly differ from the known volume of the phantoms (p = 0.74).

For volumetry of patients, tumors were identified in the coronal plane according to their above-mentioned morphology (Fig 1A and 1D). In a second step, a region of interest was manually drawn encompassing the identified tumors (Fig 1B and 1E). The software then
semi-automatically contoured individual lesions (Fig 1D and 1F). If semi-automated measurement was not feasible, tumors were traced manually using the built-in drawing tool of the MedX software[27]. The volumetry process is illustrated in Fig 1. Volumetry was performed separately for CNF and PNF in each patient which enabled determination of separate volumes for each. Summation of CNF and PNF volumes enabled calculation of whole-body tumor volume. Ten patients (5 type-1 group / 5 control group) were randomly selected and volumetry was repeated by a second reader to evaluate inter-rater reliability. Individual growth rates were calculated as the averaged annual growth in all patients with available follow-up examinations [24].

**Statistical analysis**

Continuous variables derived from tumor volumetry are presented as median ± interquartile range (IQR). All variables were evaluated for normal distribution by the Shapiro-Wilk test.
Tumor volumes (ml) were compared between the groups using the Mann-Whitney U rank sum test due to not normal distribution. Prevalence of tumors in both groups was compared using Fisher’s exact test. Measured volumes of tumor phantoms were compared with the actual volume by a paired Student’s t-test. The intraclass correlation coefficient and coefficient of variation were calculated from repeated volumetry of patients. All tests were two-sided. Growth of tumors was calculated if two MRI examinations were available. Growth rate is given as averaged annual growth in % per year. An increase in tumor volume > 20% per year was considered as progressive tumor growth [24, 29]. Tumor growth rates were compared using the Mann-Whitney U rank sum test due to not normal distribution. Patients who did not display tumors or subsets of tumors were excluded from calculation of tumor volumes and growth rates. Statistical analysis was carried out using GraphPad Prism 5.0 for Windows. P values < 0.05 were considered significant.

Results
Prevalence and distribution of tumors
Prevalence of CNF and PNF was significantly higher in the NF1 whole gene deletion group (CNF: 37/38 patients; PNF: 36/38 patients) than in the control group (CNF: 27/38 patients; PNF: 28/38 patients)(both p < 0.0001).

There was no statistically significant difference between the prevalence of CNF in the type-1 group (26/27 patients), the atypical group (11/11 patients) and the control group (27/38 patients) (all p > 0.05).

There was also no statistically significant difference between the prevalence of PNF in the type-1 group (26/27 patients), the atypical group (10/11 patients) and the control group (28/38 patients) (all p > 0.05). The prevalence of CNF and PNF within the age-dependent subgroups is provided in Table 1.

Malignant peripheral nerve sheath tumors were detected in three of the 38 patients with NF1 whole gene deletions within the observed time period (type-1 group: n = 2; atypical group: n = 1), resulting in a prevalence of 7.9% (type-1 group: 7.4%; atypical group 9.1%), respectively. None of the patients of the control group developed malignant peripheral nerve sheath tumors.

Tumor volumes
Median whole-body tumor volumes at baseline examination were: 418 ml (IQR 77–950 ml) in the type-1 group, 356 ml (IQR 140–1190 ml) in the atypical group and 49 ml (IQR 11–691 ml) in the control group. Volumes were significantly higher in the type-1 group than in the control group (p = 0.012) (Fig 2A). No significant differences were found between the type-1 group

Table 1. Prevalence of cutaneous and subcutaneous neurofibromas or plexiform neurofibromas in age-dependent subgroups of patients with either type-1 deletions of the NF1 gene, atypical deletions or without large deletions of the NF1 gene (control).

| tumor type                      | patient group    | type-1 deletion | atypical deletion | control |
|---------------------------------|------------------|-----------------|-------------------|---------|
| cutaneous and subcutaneous      | children/        | 7/8             | 3/3               | 6/12    |
| neurofibromas                   | adolescents      |                 |                   |         |
| adults                          | 19/19            | 8/8             | 21/26             |         |
| plexiform                       | children/        | 8/8             | 2/3               | 9/12    |
| neurofibromas                   | adolescents      |                 |                   |         |
| adults                          | 18/19            | 8/8             | 19/26             |         |

Presented are numbers of patients in the respective subgroups.

https://doi.org/10.1371/journal.pgen.1009517.t001
and the atypical group (p = 0.87) or between the atypical group and the control group (p = 0.099).

Volumes of CNF at baseline were: 46 ml (IQR 1–102 ml) in the type-1 group, 40 ml (IQR 6–129 ml) in the atypical group and 6 ml (IQR 0.1–26 ml) in the control group. Volumes of CNF were significantly higher in the type-1 group than in the control group (p = 0.007) and higher in the atypical group than in the control group (p = 0.013) (Fig 2B).

https://doi.org/10.1371/journal.pgen.1009517.g002
Volumes of PNF were: 382 ml (IQR 69–952 ml) in the type-1 group, 348 ml (IQR 153–1043 ml) in the atypical group and 41 ml (14–630 ml) in the control group. Volumes of PNF were significantly higher in the \( NF1 \) whole gene deletion groups than in the control group at baseline and at follow-up (Fig 2C) (all \( p < 0.05 \)). This difference was not significant when comparing the type-1 group and the atypical group (\( p = 0.79 \)).

Outliers of large tumor volumes > 3000 ml were identified in the type-1 group (n = 2) and in the atypical group (n = 1) but not in the control group (type-1 group vs control group: \( p = 0.17 \); atypical group vs control group: \( p = 0.22 \)).

Subgroup analysis revealed a significantly higher whole-body tumor volume in the type-1 group compared with the control group in adult patients (\( p = 0.019 \)). There was no significant difference between these groups in children/adolescents (\( p = 0.07 \)) (Table 2). Volumes of CNF were significantly higher in the type-1 group than in the control group in adult patients at baseline (\( p = 0.003 \)) and at follow-up (\( p = 0.037 \)) whereas volumes of CNF did not significantly differ between the groups of children / adolescents (all \( p > 0.05 \)) (Table 2). Also, volumes of PNF were significantly higher in the type-1 group than in the control group in both children / adolescents and adult patients at baseline (all \( p < 0.05 \)) (Table 2).

Table 2. Comparison of median tumor volumes at baseline and at follow-up in age-dependent subgroups of \( NF1 \) patients with type-1 deletions vs \( NF1 \) patients without large deletions of the \( NF1 \) gene (control).

| baseline/tumor type               | patient group | n   | type-1 deletion (ml) | n | control (ml) | \( p \) value |
|----------------------------------|--------------|-----|----------------------|---|--------------|--------------|
| whole-body tumor volume          | children/adolescents | 8/8 | 170.8 (55.2–782.1)   | 12/12 | 33.2 (1.0–226.9) | 0.07         |
|                                  | adults        | 19/19 | 492.7 (192.4–1312)  | 26/26 | 58.8 (10.7–805.8) | 0.019        |
|                                  | \( p \) value |          | 0.13                 |        | 0.26         |              |
| cutaneous and subcutaneous       | children/adolescents | 7/8 | 1.3 (1.0–76.3)      | 6/12 | 0.2 (0–10.2) | 0.25         |
| neurofibromas                    | adults        | 19/19 | 66.5 (36.9–116.4)   | 21/26 | 8.1 (0.8–32.7) | 0.003        |
|                                  | \( p \) value |          | 0.047                |        | 0.12         |              |
| plexiform neurofibromas          | children/adolescents | 8/8 | 106.9 (37.5–780.9)  | 9/12 | 25.3 (4.1–49.1) | 0.041        |
|                                  | adults        | 18/19 | 471 (166.8–1526)    | 19/26 | 131 (17.6–805.4) | 0.044        |
|                                  | \( p \) value |          | 0.07                 |        | 0.06         |              |
| follow-up whole-body tumor volume| children/adolescents | 8/8 | 389 (195.7–1962)    | 11/11 | 58.0 (24.3–399.3) | 0.046        |
|                                  | adults        | 14/14 | 725.8 (135.4–1167)  | 21/21 | 101.9 (18.0–1019) | 0.062        |
|                                  | \( p \)       |          | 0.811                |        | 1.0          |              |
| cutaneous and subcutaneous       | children/adolescents | 7/8 | 62.6 (7.1–174.2)    | 6/11 | 4.2 (1.0–67.2) | 0.10         |
| neurofibromas                    | adults        | 14/14 | 94.1 (26.5–162.1)   | 21/21 | 24.5 (7.8–71.2) | 0.037        |
|                                  | \( p \)       |          | 0.61                 |        | 0.16         |              |
| plexiform neurofibromas          | children/adolescents | 8/8 | 285.1 (129.2–1576)  | 9/11 | 46.5 (2.1–127.6) | 0.006        |
|                                  | adults        | 14/14 | 625.1 (173.2–1145)  | 19/21 | 129.2 (18.7–989.5) | 0.099        |
|                                  | \( p \)       |          | 0.54                 |        | 0.18         |              |

Values in parentheses represent interquartile range.

https://doi.org/10.1371/journal.pgen.1009517.t002
Details of all tumor volumes of age-dependent subgroups at baseline and at follow-up are provided in Table 2. Volumetric results for each patient are provided in supporting information S4 Table. Results of the repeated volumetry for evaluation of inter-rater reliability are provided in S5 Table.

Growth dynamics

Median averaged annual growth rates for whole-body tumor burden were: 14%/year (IQR 4.8–35.5) in the type-1 group, 11%/year (IQR 5.3–22.9) in the atypical group and 4.2%/year (IQR 1.4–8.1) in the control group. The averaged annual growth rates of whole-body tumor burden in the type-1 group and the atypical group were not significantly different (p = 0.67), but were significantly higher than in the control group (p = 0.004 and p = 0.014) (Fig 2D).

Averaged annual growth rates of CNF were: 5.1%/year (IQR 0.4–12.) in the type-1 group, 2.5%/year (IQR 0.1–4.6) in the atypical group and 2.1%/year (IQR 0–4.1) in the control group. There were no statistically significant differences between the three groups (all p > 0.05) (Fig 2E).

Averaged annual growth rates of PNF were: 12.7%/year (IQR 5.1–40.4) in the type-1 group, 12.1%/year (IQR 4.2–31) in the atypical group and 2.2%/year (IQR -0.3–4.3) in the control group. Averaged annual growth rates of PNF were not significantly different between the NF1 whole gene deletion groups (p = 0.75) but were significantly higher than in the control group (type-1 group vs control group: p < 0.0001 / atypical group vs control group: p < 0.0016) (Fig 2F).

Progressive tumor growth

Progressive tumor growth (> 20%/year) of whole-body tumor volume and of PNF was detected in 8/22 patients in the type-1 group, in 3/10 patients in the atypical group and in 2/32 patients in the control group.

The prevalence of progressive tumor growth was significantly higher in the type-1 group than in the control group (p = 0.01). The prevalence was not significantly different between the atypical group and the control group (p = 0.08) or between the type-1 group and the atypical group (p = 1.0).

Progressive tumor growth (> 20%/year) of CNF was detected in 3/22 patients in the type-1 group and in 2/32 patients in the control group whereas no patient in the atypical group showed progressive growth of CNF (all p > 0.05). An exemplary illustration of progressive tumor growth is provided in Fig 3.

Subgroup analysis of tumor growth

For subgroup analysis of tumor growth, only patients of the type-1 group and the control group were compared, due to the small number of patients in the subgroup of atypical children/adolescents with follow-up MRI examinations (n = 2). Subgroup analysis of patients with type-1 mutations included n = 8 children/adolescents and n = 14 adults. Subgroup analysis of patients without large deletions included n = 11 children/adolescents and n = 21 adults.

Highest growth rates of whole-body tumor volume were detected in the subgroup of type-1 children/adolescents with 21%/year (IQR 14.8–47.6) (Table 3). These growth rates were significantly higher than those of adult patients in the type-1 group (median growth rate 8%/year; IQR 1.4–19.1) (p = 0.014) and higher than those of children/adolescents from the control group (median growth rate 3.3%/year; IQR 0.6–7.1) (p = 0.015) (Table 3). Similarly, growth rates of both CNF (median growth rate 13.9%/year; IQR 3–45) and PNF (19.4%/year; IQR
12.2–78.4) were significantly higher in children / adolescents in the type-1 group than in any of the other subgroups (all p < 0.05) (Table 3).

Discussion

In this study, we demonstrated that NF1 caused by whole gene deletions of the NF1 gene leads to a more severe phenotype with higher tumor burden and higher averaged annual growth rates when compared with NF1 without large deletions of the NF1 gene. In particular, pediatric patients with type-1 deletions display a pronounced averaged annual growth of cutaneous and plexiform neurofibromas.

The prevalence of CNF and PNF in our study was high in the NF1 whole gene deletion group (37/38 and 36/38 patients (97% and 95%)) as well as in the control group (27/38 and 28/
38 patients (71% and 74%) and thus higher than that reported in previous studies (76–85% and 50–76%)[14, 28, 29, 36]. The higher prevalence of tumors in our study population is potentially caused by the comparatively high number of patients who received whole-body MRI scans due to clinical complaints while presenting at our clinic. The prevalence of MPNST in patients with whole-gene deletions in our study (7.9%) was comparable to others, e.g. that reported by Pasmant et al (7.1%). The prevalence of MPNST in patients without large deletions of the NF1 gene in our study (0%) was lower than that reported by Pasmant et al (3.1%), however this bias might be caused by the small number of patients included[16].

Whole-body tumor volume as well as volumes of CNF and PNF in our study were significantly higher in patients with type-1 deletions than in the control group. The median tumor volume (387 ml) in our patients with NF1 whole gene deletions was similar to previously reported whole-body tumor volumes in patients with NF1 whole gene deletions (321 ml)[28]. Furthermore, the whole-body tumor volume in our control group (49 ml) was similar to the tumor volume of the general NF1 population previously reported (18.7–107.9 ml)[22, 28, 29].

In contrast to our findings, a previous study by Kluwe et al did not identify significant differences in volumes of PNF between NF1 patients with NF1 whole gene deletions and patients without large deletions of the NF1 gene [28]. This difference in results is potentially caused by divergent inclusion criteria and divergent volumetric processing between the studies as Kluwe et al included patients with genetic mosaicism and performed volumetry only on tumors that were larger than 3 cm in longest diameter. However, in that study the prevalence of patients with a high tumor burden (> 3000 ml) was significantly increased in patients with NF1 whole gene deletions [28]. We similarly identified more patients with a high tumor burden (> 3000 ml) in the NF1 whole gene deletion groups, but this difference was not statistically significant when compared to patients without large deletions of the NF1 gene.

Subgroup analysis of tumor volumes revealed a significantly higher whole-body tumor volume and higher volumes of CNF in adult patients with type-1 deletions compared with patients in the control group. More importantly, both adults and children / adolescents with type-1 deletions displayed significantly higher volumes of PNF than age- and sex-matched patients without large deletions of the NF1 gene, further supporting the assertion that type-1

### Table 3. Median averaged annual growth rates of tumors in age-dependent subgroups of NF1 patients with type-1 deletions vs NF1 patients without large deletions of the NF1 gene (control).

| tumor type                                           | patient group       | n    | type-1 deletion | control | p  |
|------------------------------------------------------|---------------------|------|-----------------|---------|----|
| whole-body tumor                                     | children/adolescents| 8/8  | 21.0 (14.8–47.6) | 11/11   | 3.3 (0.6–7.1) | 0.0015 |
| averaged annual growth rate (%)                      | adults              | 14/14| 8.0 (1.4–19.1)   | 21/21   | 4.3 (2.0–8.5)  | 0.31  |
|                                                       | p                   | 0.014| 0.43            |         |    |
| averaged annual growth rate of cutaneous and subcutaneous neurofibromas (%) | children/adolescents | 7/8  | 13.9 (3.0–45)   | 6/11    | 0 (0–4.1)     | 0.047 |
|                                                       | adults              | 14/14| 1.8 (0.1–6.9)   | 21/21   | 2.2 (0–4.1)    | 0.69  |
|                                                       | p                   | 0.03 | 0.90            |         |    |
| averaged annual growth rate of plexiform neurofibromas (%) | children/adolescents | 8/8  | 19.4 (12.2–78.4) | 9/11    | 0 (-0.6–3.7)  | 0.0005|
|                                                       | adults              | 14/14| 8.3 (2.5–25.5)  | 19/21   | 2.8 (-0.3–5.1) | 0.013 |
|                                                       | p                   | 0.041| 0.51            |         |    |

Values in parentheses represent interquartile range.

https://doi.org/10.1371/journal.pgen.1009517.t003
deletions are associated with a more severe phenotype. The observation that young patients with type-1 deletions display higher volumes of PNF than young patients without large deletions not only supports the hypothesis that type-1 deletions of the NF1 gene are associated with a more severe phenotype of the disease, but also that this effect occurs at a young age [14–17].

We were able to demonstrate that volumetry of CNF is feasible with MedX, which has previously not been reported. Volumes of CNF were significantly higher in patients with large deletions of the NF1 gene compared with the control group. Subgroup analysis only identified a significantly higher volume of CNF in adult patients with type-1 deletions and not in children/adolescents, which contrasts the subgroup analysis of PNF. This finding underlines the different biological characteristics of PNF and CNF, as PNF are embryonically developed tumors with a different growth pattern [37].

Averaged annual growth rates of tumors were significantly higher in patients with NF1 whole gene deletions in our study. This was true for averaged annual whole-body tumor-growth and averaged annual growth of PNF, but not for averaged annual growth of CNF. Most importantly, children/adolescents with type-1 deletions showed significantly higher averaged annual growth rates of both CNF and PNF when compared with their age- and sex-matched controls or with adult patients with type-1 deletions. In comparison, patients without large deletions of the NF1 gene did not display such an accentuated averaged annual tumor-growth at a young age. The averaged annual growth rates of PNF in patients with type-1 deletions in our study (14%) were similar to the reported growth rates of PNF by Dombi et al. (14.3%) [24] and by Akshintala et al. (13.9%) [38]. These studies did not provide genotype information of the included patients. However, due to the inclusion of children and young adults with substantial tumor burden seeking treatment on clinical trials, the similar growth rates seem plausible and do not necessarily represent the average growth rates in the entirety of NF1 patients [24, 38].

Additionally, more patients in the type-1 deletion group (8/22 patients) and in the atypical deletion group (3/10 patients) displayed progressive tumor growth of PNF of > 20%/year compared with the control group (2/32 patients). The overall prevalence of progressive tumor growth in the NF1 whole gene deletion group of 34.4% (13/32 patients) was higher than that reported for the general NF1 population by Nguyen et al (13.5%) [29]. Patients without large deletions of the NF1 gene displayed lower average annual growth rates in our study, similar to the general NF1 population investigated by Nguyen et al [29]. These observations further emphasize the importance of the underlying genetic profile when investigating tumor burden and growth in NF1.

Our subgroup analysis showing an increased averaged annual tumor-growth in children/adolescents with type-1 deletions goes beyond previous studies [24, 29, 38, 39] and has important clinical implications: We detected this significantly higher averaged annual tumor growth only in patients with type-1 deletions but not in patients without large deletions of the NF1 gene. It can be reasoned that the previously reported increase of tumor growth at a young age is mainly caused by the presence of patients with type-1 deletions in the general population [24, 29, 38, 39]. The identified higher tumor burden in patients with type-1 deletions is of special interest with regard to a possible treatment of inoperable or clinically symptomatic PNF with MEK-inhibitors (MEKi) [40]. Our observation of a high prevalence of tumors and of increased averaged annual growth of tumors in young patients with type-1 deletions might additionally encourage clinicians to re-evaluate the current clinical practice. Type-1 deletions, large numbers and volumes of tumors and high growth rates have all been identified as potential risk factors for the development of MPNST [14, 20, 21, 29, 41]. Furthermore, patients with NF1 whole gene deletions are at an elevated risk of developing MPNST [42]. The findings of
this study might therefore strengthen the argument for regular MRI examinations in young patients with type-1 deletions, to monitor tumor growth and potential malignant transformation of tumors. This hypothesis should be evaluated in further prospective studies.

We did not identify statistically significant differences in averaged annual growth of tumors between NF1 patients with type-1 deletions and those with atypical deletions. This might be expected, as atypical deletions often are heterozygous and associated with genetic mosaicism, which results in a variety of phenotypes of NF1, ranging from severe forms, similar to that of the type-1 deletion to mild forms, which are clinically almost indetectable[32]. However, due to the exclusion of patients with known or suspected genetic mosaicism in this study, phenotypical differences between type-1 deletions and atypical deletions might be limited in the investigated cohort.

Since the time between the follow-up MRI examinations was variable, the averaged annual growth rates identified in this study do not necessarily represent the actual growth rates of tumors in each year included in the observed time period. As Akshintala et al. have described, tumor growth rates can vary within patients over time and some plexiform neurofibromas can also demonstrate spontaneous decrease in volume[38]. Larger, long term prospective studies with fixed intervals between follow-up MRI examinations are required to better understand the growth dynamics of NF1 associated tumors in correlation with the genotype of patients.

There are limitations to our study. Due to its retrospective nature, the time interval between baseline and follow-up examinations is not identical in all patients. It would be favorable to examine patients prospectively within a defined time frame with predefined time intervals. However, with the selection of a control group that was not only matched in age and sex but also in time interval between examinations, the effect of different observed time periods may be neglected.

Another limitation is the limited number of patients investigated, resulting in relatively small subgroups. In particular, a larger patient cohort would be favorable for the analysis of atypical NF1 deletions. Since atypical NF1 deletions occur in only 8–10% of large NF1 deletions, larger patient groups are difficult to obtain [4]. Additionally, our volumetry approach did not allow a sufficient distinction between cutaneous and subcutaneous neurofibromas as both tumor entities appear as hyperintense nodules in proximity to the skin. Our approach also does not provide total numbers of cutaneous and subcutaneous neurofibromas and can therefore not differentiate between growth of preexisting tumors and new appearance of these lesions. Despite this weakness, we demonstrate that MRI-based volumetry is a useful method to assess the total volumes of these tumors. It might be of interest to additionally investigate the numbers of cutaneous and subcutaneous neurofibromas in future studies, which was not feasible with the software used here.

In conclusion, NF1 caused by NF1 whole gene deletions leads to a more severe phenotype with higher tumor burden and higher tumor growth rates when compared to NF1 patients without large deletions of the NF1 gene. In particular, pediatric NF1 patients with type-1 deletions exhibit rapid growth of disease-associated tumors. We therefore suggest that these patients should be monitored in close intervals to evaluate tumor growth, risk of malignant transformation of tumors and with regard to evaluation for MEK1 treatment.

Supporting information
S1 Table. Individual results of the analysis of NF1 gene mutations in patients with NF1 whole gene deletions.
(XLSX)
S2 Table. Individual results of the analysis of NF1 gene mutations in patients without large deletions of the NF1 gene.
(XLSX)

S3 Table. Volumetric results of gelatin phantoms with indicated SD. Measurements were performed with MedX (V3.42). Calculated volumes represent means derived from three separate measurements.
(XLSX)

S4 Table. Individual volumetric results for all patients.
(XLSX)

S5 Table. Volumetric results of patients who were analyzed by two readers with the calculated intraclass correlation coefficients for whole body tumor volume, cutaneous neurofibromas and plexiform neurofibromas.
(XLSX)

S1 Fig. Gelatin phantoms (a, left column), T2 weighted MRI scan of phantoms (a, right column) and results of three volume measurements with indicated SD (b), performed with MedX (v3.42).
(TIF)

Author Contributions

Conceptualization: Victor-Felix Mautner, Johannes Salamon.

Data curation: Lennart Well, Kimberly Döbel.

Formal analysis: Lennart Well, Lan Kluwe.

Funding acquisition: Johannes Salamon.

Investigation: Lennart Well, Kimberly Döbel, Peter Bannas, Said Farschtschi, Victor-Felix Mautner.

Methodology: Lennart Well, Lan Kluwe, Victor-Felix Mautner.

Project administration: Victor-Felix Mautner.

Resources: Gerhard Adam.

Software: Kimberly Döbel, Lan Kluwe.

Supervision: Gerhard Adam, Victor-Felix Mautner, Johannes Salamon.

Validation: Victor-Felix Mautner, Johannes Salamon.

Visualization: Lennart Well, Peter Bannas.

Writing – original draft: Lennart Well.

Writing – review & editing: Lennart Well, Kimberly Döbel, Lan Kluwe, Peter Bannas, Said Farschtschi, Gerhard Adam, Victor-Felix Mautner, Johannes Salamon.

References

1. Huson SM, Compston DA, Harper PS. A genetic study of von Recklinghausen neurofibromatosis in southeast Wales. II. Guidelines for genetic counselling. J Med Genet. 1989; 26: 712–21. Available: http://www.ncbi.nlm.nih.gov/pubmed/2511319 https://doi.org/10.1136/jmg.26.11.712 PMID: 2511319
2. Lammert M, Friedman JM, Kluwe L, Mautner VF. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol. 2005; 141: 71–74. https://doi.org/10.1001/archderm.141.1.71 PMID: 15655144

3. Viskochil D. Genetics of neurofibromatosis 1 and the NF1 gene. Journal of Child Neurology. BC Decker Inc.; 2002. pp. 562–570. https://doi.org/10.1177/088307380201700804 PMID: 12403554

4. Kehrer-Sawatzki H, Mautner V-F, Cooper DN. Emerging genotype–phenotype relationships in patients with large NF1 deletions. Hum Genet. 2017; 136: 349–376. https://doi.org/10.1007/s00439-017-1766-y PMID: 28213670

5. MH C, van der E MN, BMH, van A CJ, B-S EJ, van der P AT, et al. Deletions Spanning the Neurofibromatosis Type 1 Gene: Implications for Genotype-Phenotype Correlations in Neurofibromatosis Type 1? Hum Mutat. 1997;9. https://doi.org/10.1002/(SICI)1098-1004(1997)9:5<458::AID-HUMU13>3.0.CO;2-1

6. Rasmussen SA, Colman SD, Ho VT, Abernathy CR, Arn PH, Weiss L, et al. Constitutional and mosaic large NF1 gene deletions in neurofibromatosis type 1. J Med Genet. 1998; 35: 468–471. https://doi.org/10.1136/jmg.35.6.468 PMID: 9643287

7. Kluwe L, Siebert R, Gesk S, Friedrich RE, Tinschert S, Kehrer-Sawatzki H, et al. Screening 500 unselected neurofibromatosis 1 patients for deletions of theNF1 gene. Hum Mutat. 2004; 23: 111–116. https://doi.org/10.1002/humu.10299 PMID: 14722914

8. Zhang J, Tong H, Fu X, Zhang Y, Liu J, Cheng R, et al. Molecular Characterization of NF1 and Neurofibromatosis Type 1 Genotype-Phenotype Correlations in a Chinese Population. Sci Rep. 2015;5. https://doi.org/10.1038/srep11291 PMID: 26056819

9. Dorschner MO, Sybert VP, Weaver M, Pletcher BA, Stephens K. NF1 microdeletion breakpoints are clustered at flanking repetitive sequences. Hum Mol Genet. 2000; 9: 35–46. https://doi.org/10.1093/hmg/9.1.35 PMID: 10587576

10. Jenne DE, Tinschert S, Reimann H, Lasinger W, Thiel G, Hameister H, et al. Molecular characterization and gene content of breakpoint boundaries in patients with neurofibromatosis type 1 with 17q11.2 microdeletions. Am J Hum Genet. 2001; 69: 516–527. https://doi.org/10.1098/s323043 PMID: 11468690

11. López-Correa C, Dorschner M, Brems H, Lázaro C, Clementi M, Upadhyaya M, et al. Recombination hotspot in NF1 microdeletion patients. Hum Mol Genet. 2001; 10: 1387–1392. https://doi.org/10.1093/hmg/10.13.1387 PMID: 11440991

12. Missiaen L, Vogt J, Bengesser K, Fu C, Mikhail F, Serra E, et al. Mosaic type-1 NF1 microdeletions as a cause of both generalized and segmental neurofibromatosis type-1 (NF1). Hum Mutat. 2011; 32: 213–219. https://doi.org/10.1002/humu.21418 PMID: 21280148

13. Summerer A, Schäfer E, Mautner VF, Missiaen L, Cooper DN, Kehrer-Sawatzki H. Ultra-deep amplicon sequencing indicates absence of low-grade mosaicism with normal cells in patients with type-1 NF1 deletions. Hum Genet. 2019; 138: 73–81. https://doi.org/10.1007/s00439-019-0288-8 PMID: 31078644

14. Mautner VF, Kluwe L, Friedrich RE, Roehl AC, Bammert S, Högel J, et al. Clinical characterisation of 29 neurofibromatosis type-1 patients with molecularly ascertained 1.4 Mb type-1 NF1 deletions. J Med Genet. 2010; 47: 623–630. https://doi.org/10.1136/jmg.2009.075937 PMID: 20543202

15. Venturini M, Guarnieri P, Natacci F, Stabile M, Tenconi R, Clementi M, et al. Mental retardation and cardiovascular malformations in NF1 microdele ted patients point to candidate genes in 17q11.2. J Med Genet. 2004; 41: 35–41. https://doi.org/10.1136/jmg.2003.014761 PMID: 14729829

16. Pasmant E, Sabbagh A, Spurlock G, Laurendeau I, Grillo E, Hamel MJ, et al. NF1 microdeletions in neurofibromatosis type 1: From genotype to phenotype. Hum Mutat. 2010;31. https://doi.org/10.1002/humu.21271 PMID: 20513137

17. Nguyen R, Mir T, Kluwe L, Jett K, Kentsch M, Mueller G, et al. Cardiac characterization of 16 patients with large NF1 gene deletions. Clin Genet. 2013; 84: 344–349. https://doi.org/10.1111/cge.12072 PMID: 23278345

18. Ducatman BS, Scheithauer BW, Piepras DG, Reiman HM, Istrup DM. Malignant peripheral nerve sheath tumors. A clinicopathologic study of 120 cases. Cancer. 1986; 57: 2006–21. Available: http://www.ncbi.nlm.nih.gov/pubmed/3082508 https://doi.org/10.1002/1097-0142(19860515)57:10<2006::aid-cncr2820571022>3.0.co;2-6 PMID: 3082508

19. Korf BR. Review Article: Clinical Features and Pathobiology of Neurofibromatosis 1. J Child Neurol. 2002; 17: 573–577. https://doi.org/10.1177/088307380201700806 PMID: 12403555

20. Evans DGR, Baser ME, Mcgaughrian J, Sharif S, Howard E, Moran A. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet. 2002; 39: 311–4. https://doi.org/10.1136/jmg.39.5.311 PMID: 12011145
21. Uusitalo E, Rantanen M, Kallionpää RA, Pöyhönen M, Leppävirta J, Ylä-Outinen H, et al. Distinctive cancer associations in patients with neurofibromatosis type 1. J Clin Oncol. 2016; 34: 1978–1986. https://doi.org/10.1200/JCO.2015.65.3576 PMID: 26926675

22. Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. Herholz K, editor. PLoS One. 2012; 7: e35711. https://doi.org/10.1371/journal.pone.0035711 PMID: 22558206

23. Jett K, Nguyen R, Arman D, Birch P, Chohan H, Farschtschi S, et al. Quantitative associations of scalp and body subcutaneous neurofibromas with internal plexiform tumors in neurofibromatosis 1. Am J Med Genet Part A. 2015; 167: 1518–1524. https://doi.org/10.1002/ajmg.a.37068 PMID: 25900062

24. Dombi E, Solomon J, Gillespie AJ, Fox E, Balis FM, Patronas N, et al. NF1 plexiform neurofibroma growth rate by volumetric MRI: relationship to age and body weight. Neurology. 2007; 68: 643–7. https://doi.org/10.1212/01.wnl.0000250332.89420.e6 PMID: 17215493

25. Mautner VF, Brenner W, Fünsterer C, Hagel C, Wenzel K, Friedrich RE. Clinical relevance of positron emission tomography and magnetic resonance imaging in the progression of internal plexiform neurofibromas in NF1. Anticancer Res. 2007; 27: 1819–22. Available: http://www.ncbi.nlm.nih.gov/pubmed/17649778 PMID: 17649778

26. Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009; 250: 665–73. https://doi.org/10.1148/radiol.2503080700 PMID: 19244040

27. Solomon J, Warren K, Dombi E, Patronas N, Widemann B. Automated detection and volume measurement of plexiform neurofibromas using magnetic resonance imaging. Comput Med Imaging Graph. 2004; 28: 257–265. https://doi.org/10.1016/j.compmedimag.2003.03.002 PMID: 15249071

28. Kluwe L, Nguyen R, Vogt J, Bengesser K, Mussetter T, Friedrich RE, et al. Internal tumor burden in neurofibromatosis Type 1 patients with large NF1 deletions. Genes, Chromosom Cancer. 2012; 51: 447–451. https://doi.org/10.1002/gcc.21931 PMID: 22294457

29. Nguyen R, Dombi E, Widemann BC, Solomon J, Fuensterer C, Kluwe L, et al. Growth dynamics of plexiform neurofibromas: a retrospective cohort study of 201 patients with neurofibromatosis 1. Orphanet J Rare Dis. 2012; 7: 75. https://doi.org/10.1186/1750-1172-7-75 PMID: 23035791

30. Mautner V-F, Asuagbor FA, Dombi E, Fünsterer C, Kluwe L, Wenzel R, et al. Assessment of benign tumor burden by whole-body MRI in patients with neurofibromatosis 1. Neuro Oncol. 2008; 10: 593–596. https://doi.org/10.1093/neuonc/noa251 PMID: 18559970

31. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13–15, 1987. Neurofibromatosis. 1988;1: 172–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/3152465

32. Kluwe L, Friedrich RE, Farschtschi SC, Hagel C, Kehrer-Sawatzki H, Mautner V-F. Null phenotype of neurofibromatosis type 1 in a carrier of a heterozygous atypical NF1 deletion due to mosaicism. Hum Mutat. 2005 [cited 6 Apr 2020]. https://doi.org/10.1002/humu.20422 PMID: 15224858

33. Kluwe L, Friedrich RE, Peiper M, Friedman J, Mautner VF. Constitutional NF1 mutations in neurofibromatosis 1 patients with malignant peripheral nerve sheath tumors. Hum Mutat. 2003; 22: 420. https://doi.org/10.1002/humu.9193 PMID: 14517963

34. Friedrich RE, Korf B, Fünsterer C, Mautner VF. Growth type of plexiform neurofibromas in NF1 determined on magnetic resonance images. Anticancer Res. 2003; 23: 949–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/12820328

35. Salamon J, Mautner VF, Adam G, Derlin T. Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors. Rofo. 2015; 187: 1084–1092. https://doi.org/10.1055/s-0035-1535050 PMID: 26333104

36. Tucker T, Wolkenstein P, Revuz J, Zeller J, Friedman JM. Association between benign and malignant peripheral nerve sheath tumors in NF1. Neurology. 2005; 65: 205–211. https://doi.org/10.1212/01.wnl.0000168830.79997.15 PMID: 16043787

37. Zheng H, Chang L, Patel N, Yang J, Lowe L, Burns DK, et al. Induction of Abnormal Proliferation by Nonmyelinating Schwann Cells Triggers Neurolibroma Formation. Cancer Cell. 2008; 13: 117–128. https://doi.org/10.1016/j.ccr.2008.01.002 PMID: 18245212

38. Akshintala S, Baldwin A, Liewehr DJ, Goodwin A, Blakey JO, Gross AM, et al. Longitudinal evaluation of peripheral nerve sheath tumors in neurofibromatosis type 1: Growth analysis of plexiform neurofibromas and distinct nodular lesions. Neuro Oncol. 2020. https://doi.org/10.1093/neuonc/noaa003 PMID: 32156268

39. Tucker T, Friedman JM, Friedrich RE, Wenzel R, Fünsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009; 46: 81–5. https://doi.org/10.1136/jmg.2008.061051 PMID: 18930997
40. Gross AM, Wolters PL, Dombi E, Baldwin A, Whitcomb P, Fisher MJ, et al. Selumetinib in Children with Inoperable Plexiform Neurofibromas. N Engl J Med. 2020; NEJMoa1912735. https://doi.org/10.1056/NEJMoa1912735 PMID: 32187457

41. Nguyen R, Jett K, Harris GJ, Cai W, Friedman JM, Mautner V-F. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol. 2014; 116: 307–13. https://doi.org/10.1007/s11060-013-1293-1 PMID: 24166582

42. De Raedt T, Brems H, Wolkenstein P, Vidaud D, Piliotti S, Perrone F, et al. Elevated risk for MPNST in NF1 microdeletion patients. Am J Hum Genet. 2003; 72: 1288–1292. https://doi.org/10.1086/374821 PMID: 12660952